"B7-H1 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory B7 antigen that contains V-type and C2 type immunoglobulin domains. It has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN and provides negative signals that control and inhibit T-cell responses. It is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION.
| Descriptor ID |
D060890
|
| MeSH Number(s) |
D12.776.467.150.300 D12.776.543.095.300 D23.050.301.285.400 D23.529.168.300
|
| Concept/Terms |
B7-H1 Antigen- B7-H1 Antigen
- Antigen, B7-H1
- B7 H1 Antigen
- Programmed Cell Death 1 Ligand 1
- B7-H1 Immune Costimulatory Protein
- B7 H1 Immune Costimulatory Protein
- PD-L1 Costimulatory Protein
- Costimulatory Protein, PD-L1
- PD L1 Costimulatory Protein
- Programmed Cell Death 1 Ligand 1 Protein
- CD274 Antigen
- Antigen, CD274
- Antigens, CD274
- CD274 Antigens
- B7H1 Immune Costimulatory Protein
|
Below are MeSH descriptors whose meaning is more general than "B7-H1 Antigen".
Below are MeSH descriptors whose meaning is more specific than "B7-H1 Antigen".
This graph shows the total number of publications written about "B7-H1 Antigen" by people in this website by year, and whether "B7-H1 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 5 | 5 |
| 2006 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 3 | 1 | 4 |
| 2014 | 4 | 3 | 7 |
| 2015 | 5 | 2 | 7 |
| 2016 | 6 | 5 | 11 |
| 2017 | 6 | 6 | 12 |
| 2018 | 12 | 9 | 21 |
| 2019 | 13 | 18 | 31 |
| 2020 | 16 | 14 | 30 |
| 2021 | 7 | 13 | 20 |
| 2022 | 2 | 14 | 16 |
| 2023 | 2 | 16 | 18 |
| 2024 | 10 | 11 | 21 |
| 2025 | 8 | 5 | 13 |
| 2026 | 2 | 4 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "B7-H1 Antigen" by people in Profiles.
-
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC. Nat Med. 2026 Sep; 32(9):3235-3247.
-
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA. 2026 Aug 11; 336(6):464-472.
-
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis. JAMA Oncol. 2026 Jul 01; 12(7):753-761.
-
Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26; 394(12):1155-1166.
-
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2026 Mar 16; 32(6):1087-1099.
-
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and Programmed Death-Ligand 1 Expression on Overall Survival in a Select Cohort From the International Association for the Study of Lung Cancer Ninth Edition Staging Database. J Thorac Oncol. 2026 Jul; 21(7):103681.
-
Tumor-initiating stem cells fine-tune the plasticity of neutrophils to sculpt a protective niche. Cancer Cell. 2026 Jan 12; 44(1):94-111.e11.
-
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression = 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity. Lung Cancer. 2025 Nov; 209:108799.
-
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 =50%: insights from the pembrolizumab 5-year global registry. J Immunother Cancer. 2025 Sep 29; 13(9).
-
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis. Lancet Oncol. 2025 Nov; 26(11):1443-1453.